XERS Research and Charts

XERS - Xeris Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-06-05 (Delayed quote data 2025-10-29)

Last 9.62	Change ⇑ +0.39 (+4.23%)	Volume 3,437,013
	Open 9.44	High 10.03	Low 9.33

8EMA (Daily) 9.19	40EMA (Daily) 8.25	50EMA (Daily) 8.02	STO (Daily) 84.699	MACD Hist (Daily) 0.053
8EMA (Weekly) 8.560	40EMA (Weekly) 6.15	50EMA (Weekly) 5.74	STO (Weekly) 91.937	MACD Hist (Weekly) 0.124


Company Profile
Xeris Pharmaceuticals Inc is a specialty pharmaceutical company leveraging its novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations. Its pipeline products are Diazepam, Pramlintide-Insulin, Self-Administered Glucagon, and others.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.